Developments in the diagnostic procedures for von Willebrand disease

Rodeghiero, 1987, Epidemiological investigation of the prevalence of von Willebrand's disease, Blood, 69, 454, 10.1182/blood.V69.2.454.454 Bowman, 2010, A prospective evaluation of the prevalence of symptomatic von Willebrand disease (VWD) in a pediatric primary care population, Pediatr Blood Cancer, 55, 171, 10.1002/pbc.22429 Werner, 1993, Prevalence of von Willebrand disease in children: a multiethnic study, J Pediatr, 123, 893, 10.1016/S0022-3476(05)80384-1 Flood, 2011, von Willebrand disease in the United States: a perspective from Wisconsin, Semin Thromb Hemost, 37, 528, 10.1055/s-0031-1281039 de Wee, 2011, Diagnosis and management of von Willebrand disease in The Netherlands, Semin Thromb Hemost, 37, 480, 10.1055/s-0031-1281032 Valentijn, 2013, Weibel‐Palade bodies: a window to von Willebrand disease, J Thromb Haemost, 11, 581, 10.1111/jth.12160 De Ceunynck, 2013, Unwinding the von Willebrand factor strings puzzle, Blood, 121, 270, 10.1182/blood-2012-07-442285 Borchiellini, 1996, Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1‐deamino‐8‐D‐arginine vasopressin in humans, Blood, 88, 2951, 10.1182/blood.V88.8.2951.bloodjournal8882951 Weiss, 1977, Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease, J Clin Invest, 60, 390, 10.1172/JCI108788 Starke, 2013, Cellular and molecular basis of von Willebrand disease: studies on blood outgrowth endothelial cells, Blood, 121, 2773, 10.1182/blood-2012-06-435727 Wang, 2013, Analysis of the storage and secretion of von Willebrand factor in blood outgrowth endothelial cells derived from patients with von Willebrand disease, Blood, 121, 2762, 10.1182/blood-2012-06-434373 Groeneveld, 2014, Storage and secretion of naturally occurring von Willebrand factor A domain variants, Br J Haematol, 167, 529, 10.1111/bjh.13074 Rydz, 2013, The C‐type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels, Blood, 121, 5228, 10.1182/blood-2012-10-457507 Sanders, 2015, von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease, Blood, 125, 3006, 10.1182/blood-2014-09-603241 Eikenboom, 2013, VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease, Blood, 121, 2336, 10.1182/blood-2012-09-455089 Sadler, 2006, Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor, J Thromb Haemost, 4, 2103, 10.1111/j.1538-7836.2006.02146.x Goodeve, 2010, The genetic basis of von Willebrand disease, Blood Rev, 24, 123, 10.1016/j.blre.2010.03.003 Bowman, 2013, The genetics of Canadian type 3 von Willebrand disease: further evidence for co‐dominant inheritance of mutant alleles, J Thromb Haemost, 11, 512, 10.1111/jth.12130 Srámek, 1995, Usefulness of patient interview in bleeding disorders, Arch Intern Med, 155, 1409, 10.1001/archinte.1995.00430130095010 Rodeghiero, 2005, The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study, J Thromb Haemost, 3, 2619, 10.1111/j.1538-7836.2005.01663.x Tosetto, 2006, A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM‐1 VWD), J Thromb Haemost, 4, 766, 10.1111/j.1538-7836.2006.01847.x Bowman, 2009, Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire, J Thromb Haemost, 7, 1418, 10.1111/j.1538-7836.2009.03499.x Tosetto, 2011, Prospective evaluation of the clinical utility of quantitative bleeding severity assessment in patients referred for hemostatic evaluation, J Thromb Haemost, 9, 1143, 10.1111/j.1538-7836.2011.04265.x Deforest, 2015, Generation and optimization of the self‐administered bleeding assessment tool and its validation as a screening test for von Willebrand disease, Haemophilia, 21, e384, 10.1111/hae.12747 Burns, 1989, Bleeding time. A guide to its diagnostic and clinical utility, Arch Pathol Lab Med, 113, 1219 Castaman, 2010, The impact of bleeding history, von Willebrand factor and PFA‐100((R)) on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM‐1VWD, Br J Haematol, 151, 245, 10.1111/j.1365-2141.2010.08333.x Kundu, 1995, Description of an in vitro platelet function analyzer–PFA‐100, Semin Thromb Hemost, 21, 106 Hayward, 2006, Platelet function analyzer (PFA)‐100 closure time in the evaluation of platelet disorders and platelet function, J Thromb Haemost, 4, 312, 10.1111/j.1538-7836.2006.01771.x Quiroga, 2004, Template bleeding time and PFA‐100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study in 148 patients, J Thromb Haemost, 2, 892, 10.1111/j.1538-7836.2004.00693.x Dean, 2000, von Willebrand disease in a pediatric‐based population – comparison of type 1 diagnostic criteria and use of the PFA‐100 and a von Willebrand factor/collagen‐binding assay, Thromb Haemost, 84, 401, 10.1055/s-0037-1614035 Cejka, 1982, Enzyme immunoassay for factor VIII‐related antigen, Clin Chem, 28, 1356, 10.1093/clinchem/28.6.1356 Veyradier, 1999, A new automated method for von Willebrand factor antigen measurement using latex particles, Thromb Haemost, 81, 320, 10.1055/s-0037-1614468 Castaman, 2010, Validation of a rapid test (VWF‐LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM‐1VWD, Thromb Res, 126, 227, 10.1016/j.thromres.2010.06.013 Zhou, 2014, Possible race and gender divergence in association of genetic variations with plasma von Willebrand factor: a study of ARIC and 1000 genome cohorts, PLoS ONE, 9, e84810, 10.1371/journal.pone.0084810 Jang, 2010, Establishment of reference intervals for von Willebrand factor antigen and eight coagulation factors in a Korean population following the Clinical and Laboratory Standards Institute guidelines, Blood Coagul Fibrinolysis, 21, 251, 10.1097/MBC.0b013e3283367931 Bellissimo, 2012, VWF mutations and new sequence variations identified in healthy controls are more frequent in the African‐American population, Blood, 119, 2135, 10.1182/blood-2011-10-384610 Gill, 1987, The effect of ABO blood group on the diagnosis of von Willebrand disease, Blood, 69, 1691, 10.1182/blood.V69.6.1691.1691 Gallinaro, 2008, A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor, Blood, 111, 3540, 10.1182/blood-2007-11-122945 Sanders, 2014, von Willebrand disease and aging: an evolving phenotype, J Thromb Haemost, 12, 1066, 10.1111/jth.12586 Rydz, 2015, Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease, Haemophilia, 21, 636, 10.1111/hae.12664 Knol, 2012, Haemostatic variables during normal menstrual cycle. A systematic review, Thromb Haemost, 107, 22, 10.1160/TH11-07-0481 van Loon, 2014, Performance related factors are the main determinants of the von Willebrand factor response to exhaustive physical exercise, PLoS ONE, 9, e91687, 10.1371/journal.pone.0091687 Castaman, 2013, Changes of von Willebrand factor during pregnancy in women with and without von Willebrand disease, Mediterr J Hematol Infect Dis, 5, e2013052, 10.4084/mjhid.2013.052 Pottinger, 1989, von Willebrand factor is an acute phase reactant in man, Thromb Res, 53, 387, 10.1016/0049-3848(89)90317-4 Sadler, 2003, von Willebrand disease type 1: a diagnosis in search of a disease, Blood, 101, 2089, 10.1182/blood-2002-09-2892 Weiss, 1973, Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content, J Clin Invest, 52, 2708, 10.1172/JCI107465 Bodó, 2015, Platelet‐dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH, J Thromb Haemost, 13, 1345, 10.1111/jth.12964 Hillarp, 2010, Improved performance characteristics of the von Willebrand factor ristocetin cofactor activity assay using a novel automated assay protocol, J Thromb Haemost, 8, 2216, 10.1111/j.1538-7836.2010.04029.x Flood, 2009, Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function, J Thromb Haemost, 7, 1832, 10.1111/j.1538-7836.2009.03594.x Flood, 2010, Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor, Blood, 116, 280, 10.1182/blood-2009-10-249102 Vanhoorelbeke, 2000, A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor, Thromb Haemost, 83, 107, 10.1055/s-0037-1613765 Federici, 2004, A sensitive ristocetin co‐factor activity assay with recombinant glycoprotein Ibalpha for the diagnosis of patients with low von Willebrand factor levels, Haematologica, 89, 77 Stufano, 2014, A two‐centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen, Haemophilia, 20, 147, 10.1111/hae.12264 Flood, 2011, Gain‐of‐function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD, Blood, 117, e67, 10.1182/blood-2010-08-299016 Patzke, 2014, Performance evaluation and multicentre study of a von Willebrand factor activity assay based on GPIb binding in the absence of ristocetin, Blood Coagul Fibrinolysis, 25, 860, 10.1097/MBC.0000000000000169 Murdock, 1997, von Willebrand factor activity detected in a monoclonal antibody‐based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use, Thromb Haemost, 78, 1272, 10.1055/s-0038-1657727 Favaloro, 2000, Discrimination of von Willebrands disease (VWD) subtypes: direct comparison of von Willebrand factor:collagen binding assay (VWF:CBA) with monoclonal antibody (MAB) based VWF‐capture systems, Thromb Haemost, 84, 541, 10.1055/s-0037-1614064 Geisen, 2014, Comparison of von Willebrand factor (VWF) activity VWF: Ac with VWF ristocetin cofactor activity VWF:RCo, Thromb Res, 134, 246, 10.1016/j.thromres.2014.04.033 Sood, 2013, Similarity in joint function limitation in Type 3 von Willebrand's disease and moderate haemophilia A, Haemophilia, 19, 595, 10.1111/hae.12119 Ruggeri, 1980, Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease, N Engl J Med, 302, 1047, 10.1056/NEJM198005083021902 Frontroth, 2010, Prospective study of low‐dose ristocetin‐induced platelet aggregation to identify type 2B von Willebrand disease (VWD) and platelet‐type VWD in children, Thromb Haemost, 104, 1158, 10.1160/TH10-04-0213 Favaloro, 2007, Differential identification of a rare form of platelet‐type (pseudo‐) von Willebrand disease (VWD) from Type 2B VWD using a simplified ristocetin‐induced‐platelet‐agglutination mixing assay and confirmed by genetic analysis, Br J Haematol, 139, 623, 10.1111/j.1365-2141.2007.06850.x Budde, 2006, Laboratory testing for von Willebrand disease: contribution of multimer analysis to diagnosis and classification, Semin Thromb Hemost, 32, 514, 10.1055/s-2006-947866 Meijer, 2006, An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation, Semin Thromb Hemost, 32, 485, 10.1055/s-2006-947862 Budde, 2008, Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM‐1VWD), J Thromb Haemost, 6, 762, 10.1111/j.1538-7836.2008.02945.x Caron, 2002, Large experience with a factor VIII binding assay of plasma von Willebrand factor using commercial reagents, Br J Haematol, 117, 716, 10.1046/j.1365-2141.2002.03488.x Pareti, 1987, Isolation and characterization of two domains of human von Willebrand factor that interact with fibrillar collagen types I and III, J Biol Chem, 262, 13835, 10.1016/S0021-9258(19)76501-6 Flood, 2015, Crucial role for the VWF A1 domain in binding to type IV collagen, Blood, 125, 2297, 10.1182/blood-2014-11-610824 Flood, 2012, Critical von Willebrand factor A1 domain residues influence type VI collagen binding, J Thromb Haemost, 10, 1417, 10.1111/j.1538-7836.2012.04746.x Hoylaerts, 1997, von Willebrand factor binds to native collagen VI primarily via its A1 domain, Biochem J, 324, 185, 10.1042/bj3240185 Favaloro, 2010, Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease, Thromb Haemost, 104, 1009, 10.1160/TH10-06-0360 Ni, 2013, Establishment and characterization of a new and stable collagen‐binding assay for the assessment of von Willebrand factor activity, Int J Lab Hematol, 35, 170, 10.1111/ijlh.12019 Flood, 2013, Collagen binding provides a sensitive screen for variant von Willebrand disease, Clin Chem, 59, 684, 10.1373/clinchem.2012.199000 Mayadas, 1989, In vitro multimerization of von Willebrand factor is triggered by low pH. Importance of the propolypeptide and free sulfhydryls, J Biol Chem, 264, 13497, 10.1016/S0021-9258(18)80024-2 Wagner, 1987, Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells, Proc Natl Acad Sci USA, 84, 1955, 10.1073/pnas.84.7.1955 van Mourik, 1999, von Willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial cell perturbation, Blood, 94, 179, 10.1182/blood.V94.1.179.413k18_179_185 Haberichter, 2006, Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival, Blood, 108, 3344, 10.1182/blood-2006-04-015065 Haberichter, 2008, Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM‐1VWD), Blood, 111, 4979, 10.1182/blood-2007-09-110940 Sztukowska, 2008, von Willebrand factor propeptide makes it easy to identify the shorter von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease, Br J Haematol, 143, 107, 10.1111/j.1365-2141.2008.07311.x Sanders, 2015, CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease, J Thromb Haemost, 13, 956, 10.1111/jth.12927 Wohner, 2015, Shear stress‐independent binding of von Willebrand factor‐type 2B mutants p. R1306Q & p.V1316M to LRP1 explains their increased clearance, J Thromb Haemost, 13, 815, 10.1111/jth.12885 Vlot, 1995, The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor, Blood, 85, 3150, 10.1182/blood.V85.11.3150.bloodjournal85113150 Eikenboom, 2002, The factor VIII/von Willebrand factor ratio discriminates between reduced synthesis and increased clearance of von Willebrand factor, Thromb Haemost, 87, 252, 10.1055/s-0037-1612981 Batlle, 2015, Molecular and clinical profile of von Willebrand disease in Spain (PCM‐EVW‐ES): proposal for a new diagnostic paradigm, Thromb Haemost, 115, 40, 10.1160/TH15-04-0282 Acquila, 2009, Multiplex ligation‐dependent probe amplification to detect a large deletion within the von Willebrand gene, Haemophilia, 15, 1346, 10.1111/j.1365-2516.2009.02078.x Mancuso, 1991, Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction, Biochemistry, 30, 253, 10.1021/bi00215a036 Goodeve, 2007, Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM‐1VWD), Blood, 109, 112, 10.1182/blood-2006-05-020784 James, 2007, The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study, Blood, 109, 145, 10.1182/blood-2006-05-021105 Cumming, 2006, An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease, Thromb Haemost, 96, 630, 10.1160/TH06-07-0383 James, 2013, Alloantibodies in von Willebrand disease, Blood, 122, 636, 10.1182/blood-2012-10-462085